Market research
VRCA Verrica Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 84M
- P/E ratio
- Not available
- Analyst target
- 14.8
- Dividend yield
- Not available
- Beta
- 1.49
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US92511W2070
- Market cap
- 84M
- P/E ratio
- Not available
- Analyst target
- 14.8
- Dividend yield
- Not available
- Beta
- 1.49
About
About Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VRCA discussion.
5 years, 4 months ago
Verrica Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 8.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Verrica Pharmaceuticals Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 69.9% to $-13M since the same quarter in the previous year.
Finally, its free cash flow grew by 19.1% to $-7M since the same quarter in the previous year.
Based on the above factors, Verrica Pharmaceuticals Inc gets an overall score of 2/5.